MTOR and clear cell adenocarcinoma: Based on these elements and results of the present study, our opinion is that the use of an mTOR inhibitor in KTRs has a strong rational in the context of metastatic RCC and can be discussed in localized clear cell carcinomas (which have in the present study an increased risk of recurrence and mortality).